Search
SOLACI Congress
HomeFileStructural heart disease

Structural heart disease

View Category

Day 2

SOLACI-SOCIME 2022 | TAVI Edited Case, by Dra. Carla Agatiello

Enjoy this edited case performed by Dr. Carla Agatiello during the SOLACI-SOCIME 2022 Congress held at Expo...
solaci -
Learn More
Day 2

SOLACI-SOCIME 2022 | Calcified Annulus, by Dr. Guering Eid Lidt (LIVE IN A BOX CASE)

Enjoy this edited case performed by Dr. Guering Eid Lidt during the SOLACI-SOCIME 2022 Congress held at...
solaci -
Learn More
Other

Peridevice Leak in Left Atrial Appendage Closure: more than one value to take into account

According to several registries, incomplete left atrial appendage (LAA) closure has been observed in up to 30%...
solaci -
Learn More
Other

Tricuspid Regurgitation: Edge-to-Edge Treatment with PASCAL

About 4% of the population suffers from tricuspid regurgitation (TR). This disease is associated with hard-to-manage heart...
solaci -
Learn More
Other

TRICVALVE in Patients with Severe Tricuspid Regurgitation: Promising Results at 6 months

Severe tricuspid regurgitation (TR) is associated with high mortality and morbidity. For patients with high surgical risk...
solaci -
Learn More
Antithrombotic Anticoagulants

Antithrombotic Therapy Post Percutaneous Left Atrial Appendage Closure

Percutaneous left atrial appendage closure (LAAO) with Watchman has FDA approval since March 2015, having shown, in...
solaci -
Learn More
Other

TRAPEUR Registry: Thrombus Trapping with Left Atrial Appendage Closure Device

Left atrial appendage closure (LAAC) devices are a good alternative for the prevention of systemic thromboembolism in...
solaci -
Learn More
Structural heart disease

TAVR, More Information Supports Its Use

TAVR has been reported beneficial in the treatment of high and intermediate risk patients but, initially, randomized...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

EMERALD II: Non-Invasive Coronary Anatomy and Physiology (CCTA) in ACS Prediction

Dr. Omar Tupayachi - 0
Despite steady progress in secondary prevention and medical treatment optimization (OMT), acute coronary syndrome (ACS) remains one of the leading causes of cardiovascular morbimortality....

Impact of Balloon Post-Dilation on the Long-Term Durability of Bioprostheses after TAVR

Dr. Juan Manuel Pérez - 0
Balloon post-dilation (BPD) during transcatheter aortic valve replacement (TAVR) allows for the optimization of prosthesis expansion and the reduction of residual paravalvular aortic regurgitation....

TAVR in Pure Native Aortic Regurgitation: Are Dedicated Devices Truly Superior?

Dr. Juan Manuel Pérez - 0
This systematic meta-analysis assessed the efficacy and safety of transcatheter aortic valve replacement (TAVR) in patients with pure native aortic regurgitation. The emergence of...

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy